Macular Degeneration

Current Location

62 Macular Degeneration Trials Near You

Power is an online platform that helps thousands of Macular Degeneration patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Gene Therapy (ADVM-022) for Age-Related Macular Degeneration

Morgantown, West Virginia
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4-16 weeks. ADVM-022 (AAV.7m8-aflibercept) is a gene therapy product being developed for the treatment of nAMD and offers the potential for sustained intraocular expression of aflibercept following a single IVT injection. ADVM-022 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50+

69 Participants Needed

OCU-10-C-110 Injection for Age-Related Macular Degeneration

Carmel, Indiana
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+

19 Participants Needed

Ixo-vec + Aflibercept for Age-Related Macular Degeneration

Detroit, Michigan
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration (nAMD). The study will evaluate a single intravitreal (IVT) injection of Ixo-vec compared to an active comparator. The primary endpoint of this study is the mean change in best corrected visual acuity (BCVA) of Ixo-vec compared to an active comparator measured at an average of Weeks 52 and 56. Safety, tolerability, and efficacy will be evaluated throughout the study.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+

284 Participants Needed

D-4517.2 for Age-Related Macular Degeneration and Diabetic Macular Edema

Morgantown, West Virginia
This trial tests a new injectable drug, D-4517.2, in people with wet AMD or DME. The drug aims to block a protein that causes harmful blood vessel growth in the eye, potentially preventing further vision loss.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

50 Participants Needed

4D-150 for Age-Related Macular Degeneration

Carmel, Indiana
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

215 Participants Needed

Iptacopan for Age-Related Macular Degeneration

Indianapolis, Indiana
This trial tests if Iptacopan capsules can prevent worsening of early or intermediate AMD in people who already have severe AMD in one eye. The goal is to see if the medication can protect eye cells and slow down vision loss.
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+

146 Participants Needed

Stem Cell Therapy for Dry Age-Related Macular Degeneration

Ann Arbor, Michigan
This trial is testing a new treatment where cells from donor eyes are transplanted into patients with dry AMD to see if it is safe and can help improve their vision. Stem cell transplantation may improve visual acuity in patients with dry age-related macular degeneration.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:55+

18 Participants Needed

MB-102 Dye for Retinal Disorders

Ann Arbor, Michigan
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1

10 Participants Needed

CG-P5 Peptide for Age-Related Macular Degeneration

Carmel, Indiana
This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:50+

45 Participants Needed

PRIMA Retinal Prosthesis for Dry Age-Related Macular Degeneration

Pittsburgh, Pennsylvania
In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry age related macular degeneration.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:60+

5 Participants Needed

Implantable Miniature Telescope for Age-Related Macular Degeneration

Ann Arbor, Michigan
The objective of the PAS-01 study is to assess the safety of the intraocular as measured by the cumulative incidence of patients who within 5 years after implantation experience persistent vision-impairing corneal edema (corneal edema leading to persistent loss of best corrected distance visual acuity \>2 lines from pre-surgery baseline level). The study will test the null hypothesis that the percentage of patients who experience persistent vision-impairing corneal edema is \>17% against the alternative that the percentage is \<17%. The null hypothesis will be rejected if the upper bound of the two-sided 95% confidence integral for the observed percentage is \<17%.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:65+

770 Participants Needed

Tarcocimab + Tabirafusp for Wet Age-Related Macular Degeneration

Carmel, Indiana
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+

675 Participants Needed

ALK-001 for Stargardt Disease

Indianapolis, Indiana
This trial tests a modified vitamin A pill called ALK-001 for people with Stargardt disease. The drug aims to prevent harmful clumps of vitamin A in the eye that cause vision loss.

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:8 - 70

160 Participants Needed

Zimura for Stargardt Disease

Ann Arbor, Michigan
This trial is testing an eye injection medication to help people with Stargardt disease, a genetic condition that leads to vision loss. The medication aims to block harmful processes in the eye to prevent further vision loss.
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 60

121 Participants Needed

ALK-001 for Stargardt Disease

Indianapolis, Indiana
This trial tests a special type of vitamin A called ALK-001 to see if it can safely slow down vision loss in people with Stargardt disease by reducing harmful substances in the eye. ALK-001 is designed to reduce the accumulation of toxic substances in the retina, which are associated with vision loss in Stargardt disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:8 - 70

200 Participants Needed

Foselutoclax for Diabetic Macular Edema

Carmel, Indiana
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

52 Participants Needed

Avacincaptad Pegol for Geographic Atrophy

West Mifflin, Pennsylvania
The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50+

278 Participants Needed

KHK4951 for Age-Related Macular Degeneration

Royal Oak, Michigan
This trial is testing special eye drops called KHK4951 to help people with a vision problem known as nAMD. The drops aim to improve vision by addressing abnormal blood vessels in the eye.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+

180 Participants Needed

BI 771716 for Age-Related Macular Degeneration

Louisville, Kentucky
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+

180 Participants Needed

BI 1584862 for Age-Related Macular Degeneration

Louisville, Kentucky
This study is open to adults aged 55 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group. Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF) and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:55+

138 Participants Needed

Why Other Patients Applied

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

HLX04-O vs Ranibizumab for Wet Age-Related Macular Degeneration

Louisville, Kentucky
This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:50+

388 Participants Needed

RBS-001 vs Eylea for Age-Related Macular Degeneration

Erie, Pennsylvania
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:50+

434 Participants Needed

AXT107 for Age-Related Macular Degeneration

Erie, Pennsylvania
The goal of this clinical trial is to understand the safety of AXT107 injected suprachoroidally in participants with nAMD. The main question\[s\] it aims to answer are: * Safety of the maximum tolerable dose of AXT107 * Bioactivity and duration of action of AXT107 injected suprachoroidally Participants will be injected with AXT107 and will be followed on a regular monitoring visits through 9 months post single injection.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:50 - 99

15 Participants Needed

AR-14034 for Age-Related Macular Degeneration

Erie, Pennsylvania
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

140 Participants Needed

RO7669330 for Age-Related Macular Degeneration

Erie, Pennsylvania
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in GA secondary to AMD after multiple unilateral intravitreal (IVT) doses.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:55+

132 Participants Needed

NT-101 Eye Drops for Age-Related Macular Degeneration

Erie, Pennsylvania
Phase 1/2 Trial NT-101 Topical Ophthalmic Solution in Patients with Wet Age-Related Macular Degeneration (AMD)
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

30 Participants Needed

EXG102-031 for Wet Age-Related Macular Degeneration

Erie, Pennsylvania
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:50+

12 Participants Needed

Microcurrent Stimulation for Age-Related Macular Degeneration

Erie, Pennsylvania
This trial evaluates a therapy that uses tiny electrical currents through the eyelid to help patients with dry age-related macular degeneration. The goal is to improve eye health by stimulating eye tissues.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50 - 100

95 Participants Needed

Oral CT1812 for Age-Related Macular Degeneration

Erie, Pennsylvania
This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

Trial Details

Trial Status:Active Not Recruiting
Age:50+

100 Participants Needed

Aflibercept for Age-Related Macular Degeneration

Erie, Pennsylvania
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD. This study is designed to fulfill the long-term safety monitoring of EXG102-031. Participants that enroll in this long-term follow-up study have been treated with EXG102-031 under the main study (EXG102-031-211).
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 1

12 Participants Needed

123

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Macular Degeneration clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Macular Degeneration clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Macular Degeneration trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Macular Degeneration is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Macular Degeneration medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Macular Degeneration clinical trials?

Most recently, we added RBS-001 vs Eylea for Age-Related Macular Degeneration, RO7669330 for Age-Related Macular Degeneration and MB-102 Dye for Retinal Disorders to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Wet Macular Degeneration Clinical Trials

Top Age-Related Macular Degeneration Clinical Trials

Top Macular Edema Clinical Trials

212 Clinical Trials near Evans, GA

207 Clinical Trials near Belzoni, MS

211 Clinical Trials near Bakersfield, CA

171 Clinical Trials near Concord, CA

Top Retinoblastoma Clinical Trials

Top Sjia Clinical Trials

Top Endometriosis Clinical Trials

Top Prostate Clinical Trials

Top Pregnancy Clinical Trials

By Trial

Stem Cell Transplant for Age-Related Macular Degeneration

OpRegen for Age-Related Macular Degeneration

Faricimab for Age-Related Macular Degeneration

PDS Implant with Ranibizumab for Age-Related Macular Degeneration

Axitinib Implant for Age-Related Macular Degeneration

Pozelimab + Cemdisiran for Macular Degeneration

Episcleral Brachytherapy for Wet Age-Related Macular Degeneration

OpRegen for Age-Related Macular Degeneration

EYP-1901 vs Aflibercept for Age-Related Macular Degeneration

QA102 for Age-Related Macular Degeneration

Corneal Crosslinking for Keratoconus

Imaging Systems for Retinal Disease

Related Searches

Top Parkinson-disease Clinical Trials

Top Ctcl Clinical Trials

Top Cholangiocarcinoma Clinical Trials

Top Cervical-cancer Clinical Trials

Parent Intervention for Binge Drinking

Characterization of Olfactory Amygdala Subregions

Top Clinical Trials near Hobart, IN

Guselkumab for Psoriasis

Community Health Interventions for Renal Disease

Genotype-Guided Irinotecan for Colorectal and Pancreatic Cancer

CAR T Cell Therapy for Brain Cancer

Tapinarof for Cutaneous Lupus

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial